Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Final update from the Phase 1/2 BRUIN study

Blood (2025) 146 (Supplement 1): 665.

https://doi.org/10.1182/blood-2025-665

Published: 2025

Journal Articles

First-in-human, open-label, Phase 1 study of a novel CD30-directed antibody-drug conjugate with a topoisomerase 1 inhibitor payload, PF-08046044 (35C), in patients with Relapsed/Refractory lymphomas: Updated safety, PK, preliminary efficacy and ctdna analysis from dose escalation

Swetha Thiruvengadam, Christina Poh, Ryan Lynch, Craig Moskowitz, Michael Spinner, Martin Hutchings, Cristina García Herce, Elizabeth Phillips, Aung Tun, Julie Vose, Mina Nayeri, Erika Rudnicki, Maria Delioukina, Michelle Fanale, Sujit Biswas, Hailing Lu, Carlo Visco

Blood (2025) 146 (Supplement 1): 155.

https://doi.org/10.1182/blood-2025-155

Published: 2025

Journal Articles

Pirtobrutinib in Relapsed/Refractory (R/R) Waldenström macroglobulinemia (WM): Up to 5 years of follow-up from the Phase 1/2 BRUIN study

Blood (2025) 146 (Supplement 1): 226.

https://doi.org/10.1182/blood-2025-226

Published: 2025

Journal Articles

Impact of broad-spectrum antibiotic exposure on outcomes following autologous stem cell transplantation for patients with relapsed diffuse large B-cell lymphoma or Hodgkin lymphoma

Mary Katherine Anderson, Valerie Shostrom, Robert Bociek, Snegha Ananth, Matthew Lunning, Julie Vose, Christopher D'Angelo

Blood (2025) 146 (Supplement 1): 8021.

https://doi.org/10.1182/blood-2025-8021

Published: 2025

Journal Articles

Sustained remissions beyond 4 years with epcoritamab monotherapy: Long term follow-up results from the pivotal EPCORE NHL-1 trial in patients with relapsed or refractory large B-cell lymphoma

Yasmin Karimi, Chan Cheah, Julie Vose, Michael Roost Clausen, David Cunningham, Umar Farooq, Tatyana Feldman, Herve Ghesquieres, Wojciech Jurczak, Kim Linton, Tycel Phillips, Won Seog Kim, Pegah Jafarinasabian, Barbara D'Angelo Månsson, Milan Geybels, Christian Eskelund, Martin Hutchings, Catherine Thieblemont

Blood (2025) 146 (Supplement 1): 5513.

https://doi.org/10.1182/blood-2025-5513

Published: 2025

Journal Articles

Durable responses in patients with large B-cell lymphoma and 3+ prior lines of therapy who either paused or discontinued epcoritamab monotherapy while in complete response

Chan Cheah, Tycel Phillips, Wojciech Jurczak, Tae Min Kim, Kim Linton, Julie Vose, Jieying Jiang, Mohammad Atiya, Christian Eskelund, Charles Kearns, Catherine Thieblemont

Blood (2025) 146 (Supplement 1): 5511.

https://doi.org/10.1182/blood-2025-5511

Published: 2025

Journal Articles

Evolution of expert and healthcare professional treatment recommendations in the management of Mantle Cell Lymphoma

Amber Williams, Kristen Rosenthal, Stephen Ansell, Ian Flinn, Brad Kahl, Tycel Phillips, Julie Vose, Timothy Quill

Blood (2025) 146 (Supplement 1): 4650.

https://doi.org/10.1182/blood-2025-4650

Published: 2025

Journal Articles

Frailty markers associated with impaired survival and hospitalization outcomes for patients with aggressive B-cell lymphoma receiving CAR T-cell therapy

Aaron Murray, Valerie Shostrom, Robert Bociek, Snegha Ananth, Julie Vose, Matthew Lunning, Tanya Wildes, Christopher D'Angelo

Blood (2025) 146 (Supplement 1): 785.

https://doi.org/10.1182/blood-2025-785

Published: 2025

Journal Articles

Interim analysis of safety and efficacy in a Phase 2 study of MB-105, a CD5.CAR T therapy for patients with relapsed/refractory T cell lymphoma

Blood (2025) 146 (Supplement 1): 775.

https://doi.org/10.1182/blood-2025-775

Published: 2025

Journal Articles

DNMT3A mutations define a unique biological and prognostic subgroup associated with cytotoxic T cells in PTCL-NOS

Blood (2022) 140 (11): 1278–1290.

https://doi.org/10.1182/blood.2021015019

Published: 2022

Includes: Supplemental data

Journal Articles

Reproducing the molecular subclassification of peripheral T-cell lymphoma–NOS by immunohistochemistry

Blood (2019) 134 (24): 2159–2170.

https://doi.org/10.1182/blood.2019000779

Published: 2019

Includes: Supplemental data

Journal Articles

Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia

Matthew Lunning, Julie Vose, Loretta Nastoupil, Nathan Fowler, Jan A. Burger, William G. Wierda, Marshall T. Schreeder, Tanya Siddiqi, Christopher R. Flowers, Jonathon B. Cohen, Peter Sportelli, Hari P. Miskin, Michael S. Weiss, Susan O’Brien

Blood (2019) 134 (21): 1811–1820.

https://doi.org/10.1182/blood.2019002118

Published: 2019

Includes: Supplemental data

Journal Articles

Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma

Blood (2019) 133 (15): 1664–1676.

https://doi.org/10.1182/blood-2018-09-872549

Published: 2019

Includes: Supplemental data

Journal Articles

Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma

Ann S. LaCasce, R. Gregory Bociek, Ahmed Sawas, Paolo Caimi, Edward Agura, Jeffrey Matous, Stephen M. Ansell, Howland E. Crosswell, Miguel Islas-Ohlmayer, Caroline Behler, Eric Cheung, Andres Forero-Torres, Julie Vose, Owen A. O’Connor, Neil Josephson, Yinghui Wang, Ranjana Advani

Blood (2018) 132 (1): 40–48.

https://doi.org/10.1182/blood-2017-11-815183

Published: 2018

Includes: Supplemental data

Journal Articles

Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targets

Blood (2017) 130 (16): 1819–1831.

https://doi.org/10.1182/blood-2017-02-767335

Published: 2017

Includes: Supplemental data

Journal Articles

Crebbp loss cooperates with Bcl2 overexpression to promote lymphoma in mice

Blood (2017) 129 (19): 2645–2656.

https://doi.org/10.1182/blood-2016-08-733469

Published: 2017

Includes: Supplemental data

Journal Articles

Brentuximab Vedotin Plus Bendamustine: A Highly Active Salvage Treatment Regimen for Patients with Relapsed or Refractory Hodgkin Lymphoma

Ann S. LaCasce, MD, Gregory Bociek, Ahmed Sawas, Paolo F. Caimi, MD, Edward Agura, Jeffrey Matous, Stephen Ansell, MD PhD, Howland Crosswell, MD, Miguel Islas-Ohlmayer, Caroline Behler, Eric Cheung, Andres Forero-Torres, Julie Vose, Owen A. O'Connor, MD, Neil Josephson, Ranjana Advani

Blood (2015) 126 (23): 3982.

https://doi.org/10.1182/blood.V126.23.3982.3982

Published: 2015

Journal Articles

Clinical Characteristics and Outcomes of Patients with Hodgkin Lymphoma with Central Nervous System Involvement: An International Multicenter Collaboration

Chan Yoon Cheah, MBBS DMedSc, Paul J Broeckelmann, MD, Alison J Moskowitz, MD, Andreas Engert, MD, Mats Jerkeman, MD PhD, Tarec Christoffer El-Galaly, Julie Vose, Diego Villa, MDMPH, Joseph M. Connors, MD, Tatyana Feldman, MD, Dai Chihara, MD PhD, Chelsea C Pinnix, MDPhD, Sarah A Milgrom, MD, Bouthaina S. Dabaja, MD, Yasuhiro Oki, MD, Michelle A. Fanale, MD

Blood (2015) 126 (23): 3865.

https://doi.org/10.1182/blood.V126.23.3865.3865

Published: 2015

Journal Articles

Ublituximab + TGR-1202 Demonstrates Activity and a Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL: Phase I Results

Matthew A. Lunning, DO, Julie Vose, Nathan Fowler, MD, Loretta Nastoupil, MD, Jan A. Burger, MD PhD, William Wierda, MD PhD, Marshall T. Schreeder, MD, Tanya Siddiqi, MD, Christopher Flowers, MD, Jonathon B. Cohen, MD, Susan Blumel, RN, BSN, Myra Miguel, RN, Kathy Cutter, RN, BSN, Emily K. Pauli, BMBS, PharmD, Ryan Handy, BS, Peter Sportelli, Hari P. Miskin, MS, Michael S. Weiss, Susan O'Brien, MD

Blood (2015) 126 (23): 1538.

https://doi.org/10.1182/blood.V126.23.1538.1538

Published: 2015

Journal Articles

IDH2 R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma

Blood (2015) 126 (15): 1741–1752.

https://doi.org/10.1182/blood-2015-05-644591

Published: 2015

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Final update from the Phase 1/2 BRUIN study

First-in-human, open-label, Phase 1 study of a novel CD30-directed antibody-drug conjugate with a topoisomerase 1 inhibitor payload, PF-08046044 (35C), in patients with Relapsed/Refractory lymphomas: Updated safety, PK, preliminary efficacy and ctdna analysis from dose escalation

Pirtobrutinib in Relapsed/Refractory (R/R) Waldenström macroglobulinemia (WM): Up to 5 years of follow-up from the Phase 1/2 BRUIN study

Impact of broad-spectrum antibiotic exposure on outcomes following autologous stem cell transplantation for patients with relapsed diffuse large B-cell lymphoma or Hodgkin lymphoma

Sustained remissions beyond 4 years with epcoritamab monotherapy: Long term follow-up results from the pivotal EPCORE NHL-1 trial in patients with relapsed or refractory large B-cell lymphoma

Durable responses in patients with large B-cell lymphoma and 3+ prior lines of therapy who either paused or discontinued epcoritamab monotherapy while in complete response

Evolution of expert and healthcare professional treatment recommendations in the management of Mantle Cell Lymphoma

Frailty markers associated with impaired survival and hospitalization outcomes for patients with aggressive B-cell lymphoma receiving CAR T-cell therapy

Interim analysis of safety and efficacy in a Phase 2 study of MB-105, a CD5.CAR T therapy for patients with relapsed/refractory T cell lymphoma

DNMT3A mutations define a unique biological and prognostic subgroup associated with cytotoxic T cells in PTCL-NOS

Reproducing the molecular subclassification of peripheral T-cell lymphoma–NOS by immunohistochemistry

Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia

Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma

Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma

Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targets

Crebbp loss cooperates with Bcl2 overexpression to promote lymphoma in mice

Brentuximab Vedotin Plus Bendamustine: A Highly Active Salvage Treatment Regimen for Patients with Relapsed or Refractory Hodgkin Lymphoma

Clinical Characteristics and Outcomes of Patients with Hodgkin Lymphoma with Central Nervous System Involvement: An International Multicenter Collaboration

Ublituximab + TGR-1202 Demonstrates Activity and a Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL: Phase I Results

IDH2 R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only